PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced: MDSC-mediated T cell activation
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Tumor-infiltrating myeloid cells such as myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) form an important component of the hypoxic tumor microenvironment. Here, we investigated the influence of hypoxia on immune checkpoint receptors (programmed death [PD]-1 and CTLA-4) and their respective ligands (PD-1 ligand 1 [PD-L1], PD-L2, CD80, and CD86) on MDSCs. We demonstrate that MDSCs at the tumor site show a differential expression of PD-L1 as compared with MDSCs from peripheral lymphoid organ (spleen). Hypoxia caused a rapid, dramatic, and selective up-regulation of PD-L1 on splenic MDSCs in tumor-bearing mice. This was not limited to MDSCs, as hypoxia also significantly increased the expression of PD-L1 on macrophages, dendritic cells, and tumor cells. Furthermore, PD-L1 up-regulation under hypoxia was dependent on hypoxia-inducible factor-1α (HIF-1α) but not HIF-2α. Chromatin immunoprecipitation and luciferase reporter assay revealed direct binding of HIF-1α to a transcriptionally active hypoxia-response element (HRE) in the PD-L1 proximal promoter. Blockade of PD-L1 under hypoxia enhanced MDSC-mediated T cell activation and was accompanied by the down-regulation of MDSCs IL-6 and IL-10. Finally, neutralizing antibodies against IL-10 under hypoxia significantly abrogated the suppressive activity of MDSCs. Simultaneous blockade of PD-L1 along with inhibition of HIF-1α may thus represent a novel approach for cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4. Blockade of PD-L1 under hypoxia down-regulates MDSC IL-6 and IL-10 and enhances T cell proliferation and function. MDSCs isolated from spleens of B16-F10 tumor-bearing mice were pretreated for 30 min on ice with 5 µg/ml control antibody (IgG) or antibody against PD-L1 (PDL1 Block) and co-cultured with splenocytes under normoxia and hypoxia for 72 h. (A and B) Effect of MDSC on proliferation of splenocytes stimulated with (A) anti-CD3/CD28 coated beads or (B) TRP-2(180–88) peptide under the indicated conditions. Cell proliferation was measured in triplicates by [3H]thymidine incorporation and expressed as counts per minute (CPM). (C and D) MDSCs were cultured with splenocytes from B16-F10 mice stimulated with anti-CD3/CD28. Intracellular IFN-γ production was evaluated by flow cytometry by gating on (C) CD3+CD8+ IFN-γ+ and (D) CD3+CD4+ IFN-γ+ populations. Statistically significant differences (indicated by asterisks) are shown (**, P < 0.005; ***, P < 0.0005). Three separate experiments (in triplicates) with the same results were performed. Error bars indicate SD. (E) SYBR-GREEN RT-qPCR was performed to evaluate the mRNA expression levels of Ldha, Car-9, Arg-1, Nos2, Ncf-1, and Cybb-1. (F) Arginase enzymatic activity measured in MDSCs under indicated conditions. (G) After 72 h of MDSC co-culture with splenocytes, supernatants were collected and assayed for nitrites. Data represents three independent experiments with SD. (H) SYBR Green RT-qPCR was performed for expression levels of IL6, IL10, Il12p70, and Tgfb1 under the indicated conditions. IL-6, IL-10, IL-12p70, and TGF-β1 cytokine production and secretion was detected by (I and J) intracellular FACS staining (isotype control is gray-shaded histogram) and (K) ELISA, respectively. Statistically significant differences (indicated by asterisks) are shown (*, P < 0.05; **, P < 0.005; ***, P < 0.0005). The experiment was performed in triplicates and repeated three times with the same results. Error bars indicate SD. (L–O) MDSCs isolated from spleens of B16-F10 tumor-bearing mice were co-cultured with splenocytes under normoxia and hypoxia for 72 h in the presence of either 10 µg/ml control antibody (IgG), anti–mouse IL-6 Functional Grade Purified neutralizing antibody (IL-6 Block) or anti–mouse IL-10 Functional Grade Purified neutralizing antibody (IL-10 Block). Effect of MDSCs on proliferation of splenocytes stimulated with (L) anti-CD3/CD28–coated beads or (M) TRP-2(180–88) peptide under the indicated conditions. Cell proliferation was measured as indicated above. MDSCs were cultured with splenocytes from B16-F10 mice stimulated with anti-CD3/CD28. Intracellular IFN-γ production was evaluated by flow cytometry by gating on (N) CD3+CD8+ IFN-γ+ and (O) CD3+CD4+ IFN-γ+ populations. Statistically significant differences (indicated by asterisks) are shown (*, P < 0.05; **, P < 0.005). Two separate experiments (in triplicates) with the same results were performed. Error bars indicate SD.](https://figures.cochat.ai/paper-figures/2ba8a156b22c410c8802e99a6f19ff08/pd-l1-is-a-novel-direct-target-of-hif-1-and-its-blockade-under-hypoxia-enhanced-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intriguingly, HIF-1α, but not HIF-2α, directly upregulates the expression of PD-L1 in macrophages, dendritic cells and bone marrow derived macrophages (BMDMs), by binding HREs within the PD-L1 promoter (Fig. 2C) [68–70].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [68]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As seen for the other cancer axes, the HIF-α dependency of PD-L1 is tumor-type dependent, with PD-L1 expression primarily HIF-1α driven in HIF-1α-dominant cancers (such as CT26 colon carcinoma and 4T1 breast carcinoma models) and HIF-2α-driven in HIF-2α-dominant cancers (ccRCC) [81, 83].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to regulating components of the innate immune response, the HIFs have been linked to modulation of the adaptive immune response through upregulation of both co-inhibitory (eg. PD-L1 and CTLA4) and co-stimulatory receptors (eg. 4–1BB, OX40) on activated T cells [80, 81].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent data indicate that hypoxia is also able to upregulate expression of PD-L1 in malignant cells via HIF-1α and HIF-2α (17).”
From Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy (2022) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Targeting HIF-1α in immunotherapy is a relatively new concept, for which proof of principle has been amply demonstrated by others (12, 23, 27).”
From Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues (2022) · cites this paper as [12]
Experimental — accuracy not yet measured
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“A large body of preclinical and clinical data indicates that antibody blockade of immune checkpoints can significantly enhance antitumor immunity (Pardoll, 2012; West et al., 2013).”
BackgroundSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 2×
“, 2012) and its ligand, PD-L1 (Brahmer et al., 2012), was shown to result in durable tumor regression and prolonged stabilization of disease in patients with advanced cancers.”
BackgroundCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 1×
“MDSCs are a heterogeneous group of relatively immature myeloid cells and several studies have described mechanisms of MDSCmediated immune suppression (Gabrilovich et al., 2012).”
BackgroundSelf-citationGreenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318 · cited 1×
“PD-1, a cell surface glycoprotein with a structure similar to cytotoxic T lymphocyte antigen 4 (CTLA-4), belongs to the B7 family of co-stimulatory/co-inhibitory molecules and plays a key part in immune regulation (Greenwald et al., 2005).”
BackgroundSubsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645 · cited 3×
“It is important to underline that our results are in complete agreement with previous findings by Youn et al. (2008), indicating that normoxic blockade of PD-L1 did not eliminate suppressive activity of MDSCs.”
BackgroundMethodResultInfluentialBlockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314 · cited 12×
“2 I) and DCs (CD11c+; Fig.”
BackgroundResultInfluentialPD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310
Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173 · cited 6×
“As shown previously by Corzo et al. (2010), we observed higher levels of Arg-1 gene expression (Fig.”
BackgroundInfluentialOxygen Sensing, Homeostasis, and Disease
Semenza, G. L. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011165 · Cited by 993 · cited 1×
“2014 Vol. 211 No. 5 781-790 www.jem.org/cgi/doi/10.1084/jem.20131916 781 Brief Definit ive Report Hypoxia is a common feature of solid tumors (Semenza, 2011).”
BackgroundInfluential
Cited by
Items 401–500 of 1,009
The role of macrophage phenotype in regulating the response to radiation therapy
Shi, X., & Shiao, S. L. (2017) · Translational research · doi:10.1016/j.trsl.2017.11.002 · Cited by 102
“HIF-1α and IFN-γ signaling also induces the expression of PD-L1 in TAMs and tumor cells which suppresses the antitumor immune response.(126) Additionally, RT causes cancer cell death partially via apoptosis which is known to induce immunosuppressive and anti-inflammatory phenotypes in macrophages as they clear dying c…”
BackgroundKheshtchin, N., Arab, S., Ajami, M., Mirzaei, R., Ashourpour, M., Mousavi-Niri, N., Khosravianfar, N., Jadidi‐Niaragh, F., Namdar, A., Noorbakhsh, F., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1879-5 · Cited by 96
Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity
Watanabe, R., Shirai, T., Namkoong, H., Zhang, H., Berry, G. J., Wallis, B. B., Schaefgen, B., Harrison, D. G., Tremmel, J. A., Giacomini, J. C., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92167 · Cited by 93
Hao, X., Ren, Y., Feng, M., Wang, Q., & Wang, Y. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111798 · Cited by 106
Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy
Hao, Z., Li, R., Wang, Y., Li, S., Hong, Z., & Han, Z. (2021) · Biomarker Research · doi:10.1186/s40364-021-00333-5 · Cited by 104
“Additionally, PD-L1 and VISTA inhibit T cell function under hypoxia [65, 66].”
BackgroundMino-Kenudson, M. A. (2016) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2016.0009 · Cited by 103
Himes, B. T., Peterson, T. E., de Mooij, T., Garcia, L. M. C., Jung, M.-Y., Uhm, S., Yan, D., Tyson, J., Jin-Lee, H. J., Parney, D., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa029 · Cited by 92
Current insight into the regulation of PD-L1 in cancer
Liu, Z., Yu, X., Xu, L., Li, Y., & Zeng, C. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00297-8 · Cited by 104
“HIF-1α and PD-L1 expression levels were positively correlated with T cell inactivation under hypoxic circumstances, and inhibiting PD-L1 expression improved bone marrow-derived suppressor cells (MDSCs)-mediated T cell activation [49].”
BackgroundNeutrophil diversity in inflammation and cancer
Carnevale, S., Ceglie, I. D., Grieco, G., Rigatelli, A., Bonavita, E., & Jaillon, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1180810 · Cited by 104
Alemohammad, H., Najafzadeh, B., Asadzadeh, Z., Baghbanzadeh, A., Ghorbaninezhad, F., Najafzadeh, A., Safarpour, H., Bernardini, R., Brunetti, O., Sonnessa, M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112516 · Cited by 92
Regulatory mechanisms of PD-L1 expression in cancer cells
Shi, Y. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2226-9 · Cited by 92
Nitric Oxide Synthase-2-Derived Nitric Oxide Drives Multiple Pathways of Breast Cancer Progression
Basudhar, D., Somasundaram, V., de Oliveira, G. A., Kesarwala, A. H., Heinecke, J. L., Cheng, R. Y. S., Glynn, S. A., Ambs, S., Wink, D. A., & Ridnour, L. A. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6813 · Cited by 100
“Importantly, blockade of PD-L1 enhances myeloid-derived suppressor cell (MDSC)mediated T-cell activation and potentiates radiation therapeutic efficacy (90, 152).”
BackgroundOcaña, M. C., Martínez‐Poveda, B., Quesada, A. R., & Medina, M. Á. (2019) · Medicinal Research Reviews · doi:10.1002/med.21511 · Cited by 91
Clinical significance of T cell metabolic reprogramming in cancer
Herbel, C., Patsoukis, N., Bardhan, K., Seth, P., Weaver, J. D., & Boussiotis, V. A. (2016) · Clinical and Translational Medicine · doi:10.1186/s40169-016-0110-9 · Cited by 102
“Moreover, hypoxia may protect tumor cells from antitumor immunity and can promote HIF1α-dependent transcriptional upregulation of PD-L1 on cancer cells and myeloid-derived suppressor cells (MDSCs) that may inhibit PD-1-expressing T cells [199, 200].”
BackgroundBlocking C5aR signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade
Zha, H., Han, X., Zhu, Y. J., Yang, F., Li, Y., Li, Q., Guo, B., & Zhu, B. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1349587 · Cited by 92
Expression of checkpoint molecules on myeloid-derived suppressor cells
Ballbach, M., Dannert, A., Singh, A., Siegmund, D. M., Handgretinger, R., Piali, L., Rieber, N. P., & Hartl, D. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.10.001 · Cited by 106
Xiao, W. L., Klement, J. D., Lu, C., Ibrahim, M. L., & Liu, K. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800129 · Cited by 96
“The functions of PD-L1 in MDSC-mediated immune suppression might be cellular context dependent (15, 21).”
BackgroundInfluentialMacrophage-Mediated Subversion of Anti-Tumour Immunity
Quaranta, V., & Schmid, M. C. (2019) · Cells · doi:10.3390/cells8070747 · Cited by 98
“PD-L1 and PD-L2 are up-regulated in macrophages in response to different stimuli including cytokines and hypoxia [74,75].”
BackgroundNaik, A., Monjazeb, A. M., & Decock, J. V. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01940 · Cited by 100
Metabolic reprograming of tumor-associated macrophages
Puthenveetil, A., & Dubey, S. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-2037 · Cited by 107
“Increased lactic acid levels induce TF HIF-1α and mTOR dependent aerobic glycolysis (85).”
BackgroundInfluentialPotential biomarker for checkpoint blockade immunotherapy and treatment strategy
Dong, Z., Wu, S.-P., Liao, R.-Q., Huang, S., & Wu, Y.-L. L. C. (2016) · Tumor Biology · doi:10.1007/s13277-016-4812-9 · Cited by 92
Slemc, L., & Kunej, T. (2016) · Tumor Biology · doi:10.1007/s13277-016-5331-4 · Cited by 100
“Examples of previously published HIF-1α interactions are presented in Table 2 [15, 33, 47] with data presented according to our proposed initia-”
MethodTargeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma
Liu, J., Liu, Y., Meng, L., Liu, K., & Ji, B. (2017) · Oncology Reports · doi:10.3892/or.2017.5722 · Cited by 90
“Hypoxia upregulates PD-L1 on mouse and human tumor cell lines and on macrophages and DCs from naive C57BL/6 mice (12).”
Hypoxia-dependent drivers of melanoma progression
D’Aguanno, S., Mallone, F., Marenco, M., Bufalo, D. D., & Moramarco, A. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01926-6 · Cited by 106
MDSCs in sepsis-induced immunosuppression and its potential therapeutic targets
Zhang, W., Fang, X., Gao, C., Song, C., He, Y., Zhou, T., Yang, X., Shang, Y., & Xu, J. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.07.007 · Cited by 108
Roles of STAT3 in the pathogenesis and treatment of glioblastoma
Fu, W., Hou, X., Dong, L., & Hou, W. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1098482 · Cited by 105
“The hypoxic tumor microenvironment significantly enhances PD-L1 expression on MDSC through directly binding of HIF-1 to the transcriptionally active hypoxia response element (HRE) in the PD-L1 proximal promoter (Noman et al., 2014).”
BackgroundKaira, K., Shimizu, K., Kitahara, S., Yajima, T., Atsumi, J., Kosaka, T., Ohtaki, Y., Higuchi, T., Oyama, T., Asao, T., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.06.022 · Cited by 92
Role of Hypoxic Stress in Regulating Tumor Immunogenicity, Resistance and Plasticity
Terry, S., Zaarour, R. F., Venkatesh, G. H., Francis, A., El‐Sayed, W., Buart, S., Bravo, P. E., Thiery, J., & Chouaïb, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103044 · Cited by 99
“Finally, we showed that hypoxia could regulate the tumor MDSC functions by direct transcriptional induction of the programmed death-ligand 1 (PD-L1) in these cells, resulting in increased MDSC-mediated T cell tolerance [77].”
BackgroundHeat Shock Proteins in Cancer Immunotherapy
Das, J. K., Xiong, X., Ren, X., Yang, J., & Song, J. J. (2019) · Journal of Oncology · doi:10.1155/2019/3267207 · Cited by 94
“Surprisingly, several independent studies have shown that HSP90 “clients proteins” like HIF1α and JAK2 modulate immune-checkpoint blockade through induction of PD1 and PD-L1 expression [59, 60], suggesting that HSP90 inhibition could be used as an effective approach to enhancing anticancer immunotherapy.”
BackgroundPKM2 Drives Hepatocellular Carcinoma Progression by Inducing Immunosuppressive Microenvironment
Li, T., Wang, S., Shen, X., Zhang, Z., Chen, M., Wang, H., Zhu, Y., Xu, D., Hu, B., Wei, R., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.589997 · Cited by 96
“Moreover, PD-L1 up-regulation under hypoxia depended onHIF-1a, and this has been reported to be related with PKM2 as a nuclear-transcription factor (38, 39).”
BackgroundCioffi, M., Trabulo, S. M., Vallespinos, M., Raj, D., Bou Kheir, T., Lin, M.-L., Begum, J., Baker, A.-M., Amgheib, A., Saif, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15450 · Cited by 87
“Blockade of CD274 diminished MDSC-mediated T cell suppression by modulation of the MDSC-produced cytokines [34].”
EZH2 regulates PD-L1 expression via HIF-1α in non-small cell lung cancer cells
Zhao, Y., Wang, X., Wu, W., Long, H., Huang, J., Wang, Z., Li, T., Tang, S., Zhu, B., & Chen, D. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.07.039 · Cited by 92
Kim, S., Jang, J.-Y., Koh, J., Kwon, D., Kim, Y. A., Paeng, J. C., Ock, C., Keam, B., Kim, M., Kim, T. M., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1407-5 · Cited by 94
“Discussion Several studies have found that HIF-1α enhances glycolysis by upregulating glycolytic enzymes [22, 23], and upregulates PD-L1 [24], which suggests a potential link between PD-L1 and glycolysis in cancer.”
Hypoxia Supports Differentiation of Terminally Exhausted CD8 T Cells
Bannoud, N., Dalotto‐Moreno, T., Kindgard, L., García, P. A., Blidner, A. G., Mariño, K. V., Rabinovich, G. A., & Croci, D. O. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660944 · Cited by 98
Balta, E., Wabnitz, G. H., & Samstag, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115736 · Cited by 88
“Moreover, MDSCs produce adenosine and result in inhibition of T cell activities [63].”
BackgroundInfluentialCancer Immunotherapies: From Efficacy to Resistance Mechanisms – Not Only Checkpoint Matters
Wang, S., Xie, K., & Liu, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690112 · Cited by 103
Hypoxia Reduction Sensitizes Refractory Cancers to Immunotherapy
Jayaprakash, P., Vignali, P. D. A., Delgoffe, G. M., & Curran, M. A. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-060619-022830 · Cited by 87
Bitsch, R., Kurzay, A., Kurt, F. G. Ö., Torre, C. D. L., Lasser, S., Lepper, A., Siebenmorgen, A., Müller, V. A., Altevogt, P., Utikal, J. S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004384 · Cited by 98
Myeloid-Derived Suppressor Cells and Radiotherapy
Jiménez‐Cortegana, C., Galassi, C., Klapp, V., Gabrilovich, D. I., & Galluzzi, L. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-1105 · Cited by 93
Knopf, P., Stowbur, D., Hoffmann, S. H. L., Hermann, N., Maurer, A., Bucher, V., Poxleitner, M., Tako, B., Sonanini, D., Krishnamachary, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01900-0 · Cited by 105
“These factors include IFN-γ secreted by tumor-infiltrating T lymphocytes [14] or hypoxia [15] within the tumor microenvironment (TME).”
BackgroundImmune Evasion by Head and Neck Cancer: Foundations for Combination Therapy
Horton, J. D., Knochelmann, H. M., Day, T. A., Paulos, C. M., & Neskey, D. M. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.02.007 · Cited by 103
“The TME is a hostile, hypoxic environment with resultant upregulation of hypoxia-inducible factor 1alpha (HIF-1α), which in turn increases expression of PD-L1 on other TME-resident immune cells [81].”
BackgroundImmune recognition of irradiated cancer cells
Wennerberg, E., Vanpouille‐Box, C., Bornstein, S., Yamazaki, T., Demaria, S., & Galluzzi, L. (2017) · Immunological Reviews · doi:10.1111/imr.12568 · Cited by 92
Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment
Gao, X., Sui, H., Zhao, S., Gao, X., Su, Y., & Qu, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.585214 · Cited by 91
TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity
Ren, Y., Qian, Y., Ai, L., Xie, Y., Gao, Y., Zhuang, Z., Chen, J., Chen, Y., & Fang, J. (2021) · Nature Communications · doi:10.1038/s41467-021-25662-9 · Cited by 95
Lim, H. X., Kim, T. S., & Poh, C. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103599 · Cited by 89
Itatani, Y., Yamamoto, T. S., Zhong, C., Molinolo, A., Ruppel, J., Hegde, P. S., Taketo, M. M., & Ferrara, N. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2008112117 · Cited by 99
“This is because tumor-associated neutrophils (TANs) and/or granulocytic myeloid-derived suppressor cells (MDSCs) have been reported to suppress anticancer immunity through expression of PD-L1 (33, 34).”
InfluentialLi, X., Liu, H., Zhou, C., Yang, X., Huang, L., Jie, H., Zeng, Z., Zheng, X., Li, W., Liu, Z., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01773-3 · Cited by 96
“Further evidence supports that HIF-1 is a major regulator of PD-L1 expression [42].”
BackgroundChang, X., Lu, X., Guo, J., & Teng, G. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.08.006 · Cited by 92
Impact of hypoxia on DNA repair and genome integrity
Kaplan, A. R., & Glazer, P. M. (2019) · Mutagenesis · doi:10.1093/mutage/gez019 · Cited by 99
“Hypoxia also upregulates PDL1 expression in a HIF-1α-dependent fashion (101,102), providing another reason that immune checkpoint inhibitor therapy may be particularly effective in highly hypoxic tumours regardless of changes in MMR status.”
BackgroundLiu, M., Wei, F., Wang, J., Yu, W., Shen, M., Liu, T., Zhang, D., Wang, Y., Ren, X., & Sun, Q. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03745-1 · Cited by 91
Zhou, Y.-J., Li, G., Wang, J., Liu, M., Wang, Z., Song, Y., Zhang, X., & Wang, X. (2023) · Blood Science · doi:10.1097/bs9.0000000000000149 · Cited by 96
Chen, Z., Zuo, X., Cai, J., Zhang, Y., Han, G., Zhang, L., Ding, W., Wu, J., & Wang, X. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00378-2 · Cited by 95
“Previous studies demonstrated that HIF-1α could transcriptionally activate PD-L1 [12, 13].”
BackgroundInfluentialKhalili‐Tanha, G., Radisky, E. S., Radisky, D. C., & Shoari, A. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06447-w · Cited by 112
“HIF-1 signaling also drives the expression of PD-L1 in both tumor cells and infiltrating immune cells, establishing a more immunosuppressive microenvironment and fueling tumor proliferation [152].”
Yu, H., Chen, Z., Ballman, K. V., Watson, M. A., Govindan, R., Lanc, I., Beer, D. G., Bueno, R., Chirieac, L. R., Chui, M. H., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.006 · Cited by 92
Photodynamic Therapy and Immune Checkpoint Blockade†
Cramer, G. M., Moon, E. K., Cengel, K. A., & Busch, T. M. (2020) · Photochemistry and Photobiology · doi:10.1111/php.13300 · Cited by 93
Targeting tumor‐associated macrophages: A potential treatment for solid tumors
Chen, Y., Jin, H., Song, Y., Huang, T., Cao, J., Tang, Q., & Zou, Z. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30139 · Cited by 82
Noncoding RNAs link metabolic reprogramming to immune microenvironment in cancers
Zhang, Y., Mao, Q., Xia, Q., Cheng, J., Huang, Z., Li, Y., Chen, P., Yang, J., Fan, X., Liang, Y., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01179-y · Cited by 88
“In turn, HIF1α and glycolysis activation contribute to PD-L1 expression and failure of immunosurveillance, as previously observed in other cells in the tumor microenvironment [99, 100].”
BackgroundZhang, Y., Du, X., He, Z., Gao, S., Ye, L., Ji, J., Yang, X., & Zhai, G. (2023) · ACS Nano · doi:10.1021/acsnano.3c01527 · Cited by 88
MYC and HIF in shaping immune response and immune metabolism
Gnanaprakasam, J. R., Sherman, J. W., & Wang, R. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.03.004 · Cited by 86
Liu, X., Ye, N., Liu, S., Guan, J., Deng, Q., Zhang, Z., Xiao, C., Ding, Z., Zhang, B., Chen, X., et al. (2021) · Advanced Science · doi:10.1002/advs.202100233 · Cited by 83
Immune evasion mechanisms in acute myeloid leukemia: A focus on immune checkpoint pathways
Taghiloo, S., & Asgarian‐Omran, H. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103164 · Cited by 93
Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT
Tumino, N., Pace, A. L. D., Besi, F., Quatrini, L., Vacca, P., & Moretta, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.638841 · Cited by 90
“In addition, other factor such as HIF-1α increases the immunosuppressive activity of MDSC by inducing Programmed Cell Death 1 (PD-1) expression and by upregulating the V-domain of Ig suppressor of T-cell activation (VISTA) (64, 65).”
BackgroundLee, K. S., Kwak, Y., Ahn, S., Shin, E. H., Oh, H., Kim, D., Kang, S., Choe, G., Kim, W. H., & Lee, H. S. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1999-6 · Cited by 84
Won, W.-J., Deshane, J. S., Leavenworth, J. W., Oliva, C. R., & Griguer, C. E. (2019) · Cell Stress · doi:10.15698/cst2019.02.176 · Cited by 89
Tumor-associated macrophages: role in tumorigenesis and immunotherapy implications
Zhu, S., Luo, Z., Li, X., Han, X., Shi, S., & Zhang, T. (2020) · Journal of Cancer · doi:10.7150/jca.49692 · Cited by 87
“In the hypoxic tumor microenvironment, TAMs enhance the expression of HIF-1and HIF-2[48, 49], and the overexpression of this factor can promote the production of the above cytokines such as VEGF [50, 51].”
BackgroundSharma, A., Sinha, S., & Shrivastava, N. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.849040 · Cited by 93
“Besides that, HIF-1α stimulates the synthesis of the immunological checkpoint protein PD-L1(programmed death ligand-1), which aids in immune suppression and evasion (Noman et al., 2014; Abou Khouzam et al., 2021).”
BackgroundMiao, L., Lu, C., Zhang, B., Li, H., Zhao, X., Chen, H., Liu, Y., & Cui, X. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05033-w · Cited by 95
“Combination therapy with a PD-L1 antibody and a HIF-1α inhibitor may improve the immune response of patients and enhance immune efficacy [80].”
MethodUnraveling the triad of hypoxia, cancer cell stemness, and drug resistance
Shang, T., Jia, Z., Li, J., Cao, H., Xu, H., Cong, L., Ma, D., Wang, X., & Liu, J. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01684-4 · Cited by 100
“Concurrently, the transcription factor HIF-1α upregulates the expression of the immune checkpoint molecules PD-L1 and PD-L2 on MDSCs, thereby transforming these cells into a central hub of immunosuppression [303].”
Zhang, X., Ashcraft, K. A., Warner, A. B., Nair, S. K., & Dewhirst, M. W. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2468 · Cited by 98
Non-coding RNAs shuttled via exosomes reshape the hypoxic tumor microenvironment
Wang, W., Han, Y., Jo, H. A., Lee, J., & Song, Y. S. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00893-3 · Cited by 87
“Moreover, HIF-1α promoted the overexpression of PDL1 in myeloid-derived suppressor cells (MDSCs) and macrophages, neutralizing anti-cancer immunity in the tumor microenvironment [22].”
BackgroundRegulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling
Glorieux, C., Xia, X., He, Y., Hu, Y., Cremer, K., Robert, A. R., Liu, J., Wang, F., Ling, J., Chiao, P. J., et al. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101780 · Cited by 85
MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC
Xie, W.-B., Liang, L.-H., Wu, K.-G., Wang, L.-X., He, X., Song, C., Wang, Y.-Q., & Li, Y.-H. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000488634 · Cited by 80
Miyoshi, Y., Yoshimura, Y., Saito, K., Muramoto, K., Sugawara, M., Alexis, K. M., Nomoto, K., Nakamura, S., Saeki, T., Watanabe, J., et al. (2020) · Breast Cancer · doi:10.1007/s12282-020-01067-2 · Cited by 82
Radiotherapy and cGAS/STING signaling: Impact on MDSCs in the tumor microenvironment
Kho, V. M., Mekers, V. E., Span, P. N., Bussink, J., & Adema, G. J. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104298 · Cited by 93
Immunotherapy of targeting MDSCs in tumor microenvironment
Sui, H., Dongye, S., Liu, X., Xu, X., Wang, L., Jin, C. Q., Yao, M., Gong, Z., Jiang, D., Zhang, K., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.990463 · Cited by 87
“Thus, co-blocking of PD-L1 and HIF1a reduces the immunosuppressive activity of both MDSCs and TAMs to inhibit tumor development (83).”
BackgroundIbrahim, A., Abdalsalam, N. M. F., Liang, Z., Tariq, H. K., Li, R., Afolabi, L. O., Rabiu, L., Chen, X., Xu, S., Xu, Z., et al. (2025) · Cancer Gene Therapy · doi:10.1038/s41417-025-00886-9 · Cited by 101
Myeloid-derived suppressor cells and tumor escape from immune surveillance
Umansky, V., Blattner, C., Fleming, V., Hu, X., Gebhardt, C., Altevogt, P., & Utikal, J. S. (2016) · Seminars in Immunopathology · doi:10.1007/s00281-016-0597-6 · Cited by 85
“In addition, the upregulation of PD-L1 expression on MDSCs in mouse tumor models was found also to be strongly stimulated by HIF-1α under hypoxia conditions [47].”
BackgroundInfluentialEmerging predictors of the response to the blockade of immune checkpoints in cancer therapy
Li, X., Song, W., Shao, C., Shi, Y., & Han, W. (2018) · Cellular and Molecular Immunology · doi:10.1038/s41423-018-0086-z · Cited by 81
Noman, M. Z., Van Moer, K., Marani, V., Gemmill, R. M., Tranchevent, L.-C., Azuaje, F., Muller, A., Chouaib, S., Thiery, J. P., Berchem, G., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1345415 · Cited by 78
Self-citationPredictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
Shen, H., Yang, E. S.-H., Conry, M., Fiveash, J. B., Contreras, C. M., Bonner, J. A., & Shi, L. Z. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.06.006 · Cited by 84
Effects of Radiation on the Tumor Microenvironment
Monjazeb, A. M., Schalper, K. A., Villarroel‐Espíndola, F., Nguyen, A. T., Shiao, S. L., & Young, K. H. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2019.12.004 · Cited by 93
MDSC in Mice and Men: Mechanisms of Immunosuppression in Cancer
Vanhaver, C., van der Bruggen, P., & Bruger, A. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132872 · Cited by 84
“[79,80] PD-L1+ M- and PMN-MDSCs accumulate in blood of cancer patients.”
BackgroundZiani, L., Buart, S., Chouaïb, S., & Thiery, J. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1950953 · Cited by 85
“Of note, some of the genes encoding these immunosuppressive factors have been described as direct target of HIF-1α transcription factor, including VEGF,53 TGF-β,54,55 IL-10,56 MMP-957 or PD-L1.”
BackgroundInfluentialAtat, O. E., Farzaneh, Z., Pourhamzeh, M., Taki, F., Abi‐Habib, R. J., Vosough, M., & El‐Sibai, M. (2021) · Human Cell · doi:10.1007/s13577-021-00642-9 · Cited by 87
TCR engineered T cells for solid tumor immunotherapy
Zhang, Y., Liu, Z., Wei, W., & Li, Y. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00291-0 · Cited by 87
“PD-L1 binds to the programmed cell death protein 1 (PD-1) on T cells and then mediates T cell exhaustion [104].”
BackgroundLin, Q., Wang, X., & Hu, Y. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216318 · Cited by 78
Li, N., Wang, J., Zhang, N., Zhuang, M., Zong, Z., Zou, J., Li, G., Wang, X., Zhou, H., Zhang, L., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2086-8 · Cited by 80
“The expression of B7-H1 in tumor cells or immune cells inhibits the proliferation of T cells or leads to apoptosis or exhaustion of T cells [37, 42, 43].”
BackgroundSingh, S., & Chakrabarti, R. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050642 · Cited by 79
“These activated MDSCs express CD40 and PD-L1, which suppress the antitumor response of T cells [132,133].”
BackgroundMDSCs in liver cancer: A critical tumor-promoting player and a potential therapeutic target
Ma, C., Zhang, Q., & Greten, T. F. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104295 · Cited by 81
“Tumor MDSCs express ligands for inhibitory checkpoint receptors such as PD-L1 and CTLA-4, and tumor-associated hypoxia via hypoxia-inducible factor 1-α (HIF1α) helps upregulate PD-L1 expression on the surface of tumor MDSCs[67].”
BackgroundThe Complex Tumor Microenvironment in Ovarian Cancer: Therapeutic Challenges and Opportunities
Garlisi, B., Lauks, S., Aitken, C., Ogilvie, L. M., Lockington, C., Petrik, D., Eichhorn, J. S., & Petrik, J. (2024) · Current Oncology · doi:10.3390/curroncol31070283 · Cited by 100
Lu, Y., Liu, H., Bi, Y., Yang, H., Li, Y., Wang, J., Zhang, Z., Wang, Y., Li, C., Jia, A., et al. (2017) · Cellular and Molecular Immunology · doi:10.1038/cmi.2017.5 · Cited by 85
Therapeutic strategies to remodel immunologically cold tumors
Wang, M., Wang, S., Desai, J., Trapani, J. A., & Neeson, P. J. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1226 · Cited by 87
“Studies have shown that hypoxia drives recruitment of MDSCs and tumor-associated macrophage.(118,119) Jayaprakash et al.”
BackgroundLiu, X., Xing, Y., Li, M., Zhang, Z., Wang, J., Ri, M., Jin, C. H., Xu, G., Piao, L. X., Jin, H., et al. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.113989 · Cited by 82
You, L., Zhao, Y., Kuča, K., Wang, X., Olekšák, P., Chrienová, Ž., Nepovimová, E., Jacevic, V. M., Wu, Q., & Wu, W. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03030-2 · Cited by 81
Tumour Microenvironment Stress Promotes the Development of Drug Resistance
Seebacher, N. A., Krchniaková, M., Stacy, A. E., Skoda, J., & Jansson, P. J. (2021) · Antioxidants · doi:10.3390/antiox10111801 · Cited by 89
“These transcription factors collectively alter the expression of hundreds of genes involved in tumourigenesis and regulate the expression of immune checkpoints (CTLA-4, PD-L1), cell-cycle regulatory molecules (cyclin D1, TGF-α) and important genes required for cell transformation, proliferation, and metastasis (PTEN,…”
BackgroundChen, T., Wu, C., Wang, C., Hsu, W., Yang, T., Lou, P., Ko, J., & Chang, Y. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2015.08.011 · Cited by 80
Proia, D. A., & Kaufmann, G. F. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0057 · Cited by 77
Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer
Cowman, S. J., Fuja, D. G., Liu, X.-D., Tidwell, R. S. S., Kandula, N., Sirohi, D., Agarwal, A. M., Emerson, L. L., Tripp, S. R., Mohlman, J. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3890 · Cited by 76
Energy metabolic pathways control the fate and function of myeloid immune cells
Al-Khami, A. A., Rodríguez, P. C., & Ochoa, A. C. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.1vmr1216-535r · Cited by 80
Neutrophils as myeloid‐derived suppressor cells
Aarts, C. E. M., & Kuijpers, T. W. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.12989 · Cited by 82
Metadata
- Authors
- Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S.
- Affiliations
- Inserm (FR)
- Istituto Oncologico Veneto (IT)
- Centre de Recherche Public de la Santé (LU)
- Institut Gustave Roussy (FR)
- University of Verona (IT)
- Unité Institut National de la Santé et de la Recherche Médicale U753, Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France 1
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2014-04-28
- Volume
- 211
- Issue
- 5
- Pages
- 781-790
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC4010891
- OpenAlex
- W2149360266
- Semantic Scholar
- dad078dcb463c50f1571acb3306b01954a153c29
- Cited by
- 2,166
- References
- 24
- Citations by year
- 2026: 171 · 2025: 187 · 2024: 208 · 2023: 219 · 2022: 239 · 2021: 331 · 2020: 224 · 2019: 147 · 2018: 139 · 2017: 120 · 2016: 101 · 2015: 61 · 2014: 18
- FWCI
- 48.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-L1, HIF-1α, hypoxia, myeloid-derived suppressor cells, tumor microenvironment, immune checkpoint blockade, T cell activation, hypoxia response element, IL-10, interleukin-6, tumor-associated macrophages, cancer immunotherapy, CTLA-4, PD-1 ligands
- MeSH terms
- Animals, Diamines, Enzyme-Linked Immunosorbent Assay, Female, Flow Cytometry, Gene Expression Regulation, Luciferases, Lymphocyte Activation, Mice, Inbred C57BL, Organic Chemicals, Quinolines, T-Lymphocytes, Cell Hypoxia, Myeloid Cells, RNA Interference, Chromatin Immunoprecipitation, Mice, Hypoxia-Inducible Factor 1, alpha Subunit, Benzothiazoles, Tumor Microenvironment, Real-Time Polymerase Chain Reaction, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.